



JW

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10593261
Filing Date	2007-07-11
First Named Inventor	Lars Michael Larsen
Art Unit	1614
Examiner Name	
Attorney Docket Number	LARSEN=5

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5552369		1996-09-03	FINDEISEN et al.	
	2	5624949		1997-04-29	William E. HEATH Jr. et al.	
	3	5674862		1997-10-07	William E. HEATH Jr. et al.	
	4	5698578		1997-12-16	William E. HEATH Jr. et al.	
	5	5710145		1998-01-20	Gaey Lowell ENGEL et al.	
	6	5824685		1998-10-20	Peter A. CAMPOCHIARO et al.	
	7	6015807		2000-01-18	Gaey Lowell ENGEL et al.	
	8	6114320		2000-09-05	Lloyd P. AIELLO et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10593261
Filing Date	2007-07-11
First Named Inventor	Lars Michael Larsen
Art Unit	1614
Examiner Name	
Attorney Docket Number	LARSEN=5

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030032078	A1	2003-02-13	Gabriel H. TRAVIS	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2005107707	WO	A1	2005-11-17	Allergan, Inc.		<input type="checkbox"/>
	2	02080936	WO	A1	2002-10-17	Ortho McNeil Pharmaceutical, Inc.		<input type="checkbox"/>
	3	2005058304	WO	A1	2005-06-30	Cortical Pty Ltd.		<input type="checkbox"/>
	4	03104178	WO	A1	2003-12-18	Cortical Pty Ltd.		<input type="checkbox"/>
	5	02080935	WO	A1	2002-10-17	Ortho McNeil Pharmaceutical, Inc.		<input type="checkbox"/>
	6	03097052	WO	A2	2003-11-27	Celgene Corporation		<input type="checkbox"/>
	7	99058126	WO	A1	1999-11-18	The Endowment for Research in Human Biology, Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10593261
Filing Date	2007-07-11
First Named Inventor	Lars Michael Larsen
Art Unit	1614
Examiner Name	
Attorney Docket Number	LARSEN=5

8	02072003	WO	A2	2002-09-19	Tomas HAGSTROM		<input type="checkbox"/>
9	02085400	WO	A1	2002-10-31	Supergen, Inc.		<input type="checkbox"/>
10	0198294	WO	A2	2001-12-27	Dupont Pharmaceuticals Company		<input type="checkbox"/>
11	03004058	WO	A1	2003-01-16	Santen Pharmaceutical Co.	Abstract	<input checked="" type="checkbox"/>
12	2005056010	WO	A1	2005-06-23	Allergan, Inc.		<input type="checkbox"/>
13	2005011741	WO	A2	2005-02-10	Allergan, Inc.		<input type="checkbox"/>
14	03082081	WO	A2	2003-10-09	Maxim Pharmaceuticals, Inc.		<input type="checkbox"/>
15	0522226	EP	A1	1993-01-13	Ciro COSTAGLIOLA		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	PAUL A. SIEVING et al. "Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy", Proc. Nat. Acad. Sci. (USA), February 13, 2001, Vol. 98, No. 4, pages 1835-1840	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10593261
Filing Date	2007-07-11
First Named Inventor	Lars Michael Larsen
Art Unit	1614
Examiner Name	
Attorney Docket Number	LARSEN=5

2	ROXANA A. RADU et al., "Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration", Proc. Nat. Acad. Sci. (USA), April 15, 2003, Vol. 100, No. 8, pages 4742-4747	<input type="checkbox"/>
3	JANET R. SPARROW, "Therapy for macular degeneration: Insights from acne", PNAS, April 15, 2003, Vol. 100, No. 8, pages 4353-4354	<input type="checkbox"/>
4	G. B. ARDEN, "The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible", Br J Ophthalmol, 2001, Vol 85, pages 366-370	<input type="checkbox"/>
5	LERMAN, S., "Ocular side effects of accutane therapy", Lens and Eye Toxicity Research, 1992, Vol. 9(3-4), pages 429-38.	<input type="checkbox"/>
6	DEVIPRASAD R. GOLLAPALLI et al., "Specific inactivation of isomerohydrolase activity by 11-cis-retinoids", Science Direct, Biochimica et Biophysica Acta 1651 (2003) pages 93-101	<input type="checkbox"/>
7	DEVIPRASAD R. GOLLAPALLI et al., "All-trans-retinyl Esters Are the Substrates for Isomerization in the Vertebrate Visual Cycle", Biochemistry, April 25, 2003, Vol. 42 pages 5809-5818	<input type="checkbox"/>
8	DEVIPRASAD R. GOLLAPALLI et al., "RPE65 Operates in the Vertebrate Visual Cycle by Stereospecifically Binding All-trans-Retinyl Esters", Biochemistry, September 17, 2003, Vol. 42, pages 11824-11830	<input type="checkbox"/>
9	PAUL S. BERNSTEIN et al., "Mechanism of Action of Aromatic Amines That Short-Circuit the Visual Cycle", Biochemistry, 1986, Vol. 25, pages 3370-3377	<input type="checkbox"/>
10	N DRASDO et al., "Effect of darkness on inner retinal hypoxia in diabetes" The Lancet, Vol. 359, June 29, 2002, pages 2251-2253	<input type="checkbox"/>
11	ANETTE WINSTON et al., "Regulation of Isomerohydrolase Activity in the Visual Cycle", Biochemistry, February 3, 1998, Vol. 37, pages 2044-2050	<input type="checkbox"/>
12	G.B. ARDEN et al., "Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis", Vision Research, Vol. 38, 1998, pages 1723-1729	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10593261
Filing Date	2007-07-11
First Named Inventor	Lars Michael Larsen
Art Unit	1614
Examiner Name	
Attorney Docket Number	LARSEN=5

13	ANNA WROBEL et al., "Antiangiogenic activity of agonist and antagonists of retinoid nuclear receptors", Przeglad Dermatologiczny, 1999, Vol. 86, No. 4, pages 339-346 (in Polish)	<input checked="" type="checkbox"/>
14	MICHAEL F. MARMOR, et al., "Albipunctate Retinopathy with cone Dysfunction and no Abnormality in the RDH5 or RLBPI Genes", Retina 2003 United States, Vol. 23, Vol. 4, pages 543-546	<input type="checkbox"/>
15	B. M. CALISSENDORFF, "Retinal changes degeneration or side effects caused by etretinate therapy Tigason" Klin. Mbl. Augenheilk, Vol. 194, 1989, pages 187-189 (in German)	<input checked="" type="checkbox"/>
16	TSUTOMU OIKAWA et al., "Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo", Europ J. of Pharmac., Vol. 249, 1993, pages 113-116	<input type="checkbox"/>
17	SELIG HECHT et al., "Rod-Cone Dark Adaptation and Vitamin A", Science, New Series, Vol. 88, No. 2279, September 2, 1938, pages 219-221	<input type="checkbox"/>
18	JOHN E. DOWLING et al., "Vitamin a Deficiency and Night Blindness", Proc. Natl. Acad. Sci. USA Vol. 44, (1958) pages 648-661	<input type="checkbox"/>
19	RICHARD G. WELEBER et al., "Abnormal Retinal Function Associated with Isotretinoin Therapy for Acne", Arch Ophthalmol, Vol. 104, June 1986, pages 831-837	<input type="checkbox"/>
20	H. MACLEAN et al., "Abnormal night vision with isotretinoin therapy for acne", Clinical and Experimental Dermatol, Vol. 20, page 86, January 1995,	<input type="checkbox"/>
21	ROSALIE K. CROUCH et al., "Retinoids and the Visual Process", Photochem. Photobiol., Vol. 64, pages 613-621	<input type="checkbox"/>
22	F. T. FRAUNFELDER, et al., "Ocular Side Effects Possibly Associated with Isotretinoin Usage", Am. J. Ophthalmol, Vol. 132, 2001, pages 299-305	<input type="checkbox"/>
23	WING C. LAW et al., "The Molecular Basis of Retinoic Acid Induced Night Blindness" Biochem. Biophys. Res. Comm., Vol. 161, No. 2, pages 825-829	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10593261
Filing Date	2007-07-11
First Named Inventor	Lars Michael Larsen
Art Unit	1614
Examiner Name	
Attorney Docket Number	LARSEN=5

24 BELINDA M. WELSH et al., "Night blindness precipitated by isotretinoin in the setting of hypovitaminosis A", Australas J Dermatol, Vol. 40, 1999, pages 208-210

25 G. P. MOSS et al., "Nomenclature of Retinoids", Arch. Biochem., Biophys. Vol. 224, No. 2, July 15, 1983, pages 728-731

26 BRAHMA P. SANI et al., "Structural Characteristics of Synthetic Retinoids", Meth. In Enzymology, Vol. 189, 1990, pages 43-59

27 MICHAEL KLAUS, "Structure Characteristics of Natural and Synthetic Retinoids" Meth. In Enzymology, Vol. 189, (1990) pages 3-14

28 M. I. DAWSON et al., "Synthetic Retinoic Acid Analogs: Handling and Characterization", Meth. In Enzymology, Vol. 189, , 1990, pages 15-43

29 GREGORY M. ACLAND et al., "Gene therapy restores vision in a canine model of childhood blindness", Nature genetics, Vol. 28, May 2001, pages 92-95

30 T. MICHAEL REDMOND et al., "Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle", Nature Genetics, Vol. 20, December 1998, pages 344-351

31 PAUL S. BERNSTEIN et al., "The Specific Inhibition of 11-cis-Retinyl Palmitate Formation in the Frog Eye by Diaminophenoxyptane, An inhibitor of Rhodopsin Regeneration", Vision Res., Vol. 25, No. 6, 1985, pages 741-748

32 BROWN, et al., "Visual toxicity of synthetic retinoids", British Journal of Ophthalmology, Vol. 73, pages 286-288, 1989.

33 CAFFERY, et al., "Ocular side effects of isotretinoin therapy", Journal of the American Optometric Association, Vol. 59, No. 3, pages 221-224, March 1988.

34 DENMAN, et al., Abnormal night vision and altered dark adaptometry in patients treated with isotretinoin for acne", Journal of the American Academy of Dermatology, Vol. 14, No. 4, pages 692-693, April 1986.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10593261
Filing Date	2007-07-11
First Named Inventor	Lars Michael Larsen
Art Unit	1614
Examiner Name	
Attorney Docket Number	LARSEN=5

35	FEIST, et al., "Visual Side Effects of Isotretinoin Therapy", SOUTHERN MEDICAL JOURNAL, Vol. 80, No. 10, page 1332, October 1987.	<input type="checkbox"/>
36	FRAUNFELDER, et al., "Adverse Ocular Reactions Possibly Associated with Isotretinoin", American Journal of Ophthalmology, Vol. 100, pages 534-537, October 1985.	<input type="checkbox"/>
37	GROSS, et al., "Retinoids and the Eye", Dermatologic Clinics, Vol. 10, No. 3, pages 521-531, July 1992.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.